home / stock / ruby / ruby news

RUBY News and Press, Rubius Therapeutics Inc. From 09/26/19

Stock Information
Company Name: Rubius Therapeutics Inc.
Stock Symbol: RUBY
Market: OTC
Website: rubiustx.com
Menu
RUBY RUBY Quote RUBY Short RUBY News RUBY Articles RUBY Message Board
Get RUBY Alerts

News, Short Squeeze, Breakout and More Instantly...
RUBY - BioMarin readies study of gene therapy for PKU

BioMarin Pharmaceutical ( BMRN -0.5% ) has submitted an application to UK regulators seeking signoff to launch a Phase 1/2 clinical trial evaluating a single administration of BMN 307 in patients with phenylketonuria (PKU), a rare inborn error of metabolism that causes the amino acid phe...
RUBY - Rubius Therapeutics to Participate in 17th Annual Morgan Stanley Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced  that Pablo J. Cagnoni, M.D., ...

RUBY - Rubius Therapeutics Reports Second Quarter 2019 Financial Results and Operational Progress

On Track to Report Initial Clinical Data from Phase 1b Clinical Trial of RTX-134 for Phenylketonuria by Year-End CAMBRIDGE, Mass., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red bl...

RUBY - Rubius Therapeutics to Announce Second Quarter 2019 Financial Results

CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced plans to report second quarter...
RUBY - Rubius Therapeutics Appoints Kris Elverum as Senior Vice President of Business Development and Strategy

CAMBRIDGE, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, today announced the appointment of Kris Elveru...

RUBY - Leerink upgrades AbbVie in premarket analyst action

Baxter International (NYSE: BAX ) initiated with Sector Weight rating at KeyBanc. More news on: Baxter International Inc., Kadmon Holdings, Inc., Matinas BioPharma Holdings, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

RUBY - Rubius Therapeutics (RUBY) Presents At Jefferies 2019 Healthcare Conference - Slideshow

The following slide deck was published by Rubius Therapeutics, Inc. in conjunction with this Read more ...

RUBY - Rubius Therapeutics Announces Issuance of Multiple U.S. Patents for its Red Cell Therapeutic Programs

CAMBRIDGE, Mass., June 05, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of allogeneic, off-the-shelf cellular medicines, today announced the...

RUBY - Wells Fargo likes Molina after Investor Day

Allogene Therapeutics (NASDAQ: ALLO ) initiated with Neutral rating at Guggenheim. More news on: Allogene Therapeutics, Inc., Fate Therapeutics, Inc., Rubius Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

RUBY - Rubius Therapeutics to Present at Jefferies 2019 Healthcare Conference

CAMBRIDGE, Mass., May 28, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY),  a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new class of cellular medicines, announced today that Pablo J. Cagnon...
Previous 10 Next 10